4Basebio PLC
LSE:4BB
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| UK |
4
|
4Basebio PLC
LSE:4BB
|
88.3m GBP |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
395.1B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
204.9B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
190B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.3B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.5B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.4B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -1 510% |
| 30th Percentile | 0.4% |
| Median | 0.5% |
| 70th Percentile | 0.7% |
| Max | 7 323.1% |
Other Profitability Ratios
4Basebio PLC
Glance View
4basebio Plc develops gene therapy technologies and solutions. The firm is engaged in developing next generation gene therapy technologies and solutions. The firm is focused on supplying therapeutic deoxyribonucleic (DNA) for gene therapies and DNA vaccines and also for providing solutions for delivery of the DNA based products to patients. The firm focuses to manufacture and supply synthetic DNA for research, therapeutic and pharmacological use. Its TruePrime DNA amplification technology is a primer free DNA amplification method using enzymes. Its Hermes is a non-viral delivery platform that can be used to deliver various payloads, ranging from DNA to small interfering ribonucleic acid (siRNA), as well as protein cargoes. The company also offers a messenger ribonucleic acid (mRNA) production service from the DNA template it makes. The company offers a range of services including production of synthetic DNA and RNA payloads, design and assembly of payloads in nanoparticles.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for 4Basebio PLC is 61.6%, which is below its 3-year median of 69.3%.
Over the last 3 years, 4Basebio PLC’s Gross Margin has decreased from 78.5% to 61.6%. During this period, it reached a low of 61.6% on Jun 30, 2025 and a high of 89.2% on Dec 31, 2022.
